Takeda与AI Biotech Iambic合作, 为AI驱动的癌症、炎症和GI疾病药物发现支付1.7B美元。 Takeda partners with AI biotech Iambic, paying up to $1.7B for AI-driven drug discovery in cancer, inflammation, and GI diseases.

Takeda制药公司与设在圣地亚哥的AI 生物技术Iambic治疗机构进行了多年合作,承诺为AI驱动的肿瘤、炎症和肠胃疾病药物发现支付17亿多美元的潜在费用。 Takeda Pharmaceutical has entered a multi-year collaboration with San Diego-based AI biotech Iambic Therapeutics, committing over $1.7 billion in potential payments for AI-driven drug discovery in oncology, inflammation, and gastrointestinal diseases. IMBic将利用其AI平台确定小分子药物候选者,由Takeda提供预付付款和里程碑式补偿。 Iambic will use its AI platform to identify small-molecule drug candidates, with Takeda providing upfront payments and milestone-based compensation. 这笔交易标志着IMBIC自2025年筹集1亿美元以来的首个主要商业伙伴关系,并反映了工业界日益依赖人工智能来简化药物开发。 The deal marks Iambic’s first major commercial partnership since raising $100 million in 2025 and reflects growing industry reliance on artificial intelligence to streamline drug development.